Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-101 in Wet AMD
NCT06704009Phase 2Completed
- Sponsor
- NexThera Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NT-101 in exudative macular degeneration (2 arms), sponsored by NexThera Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 8 weeks. Started Mar 2025; status: completed.
02
Drugs
NT-101
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06704009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704009.